These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15123399)

  • 1. Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part II: what do I tell my patients?
    Moyad MA
    Urol Clin North Am; 2004 May; 31(2):199-205. PubMed ID: 15123399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part I: what do I tell my patients?
    Moyad MA
    Urol Clin North Am; 2004 May; 31(2):195-8. PubMed ID: 15123398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving overall men's health and potentially reducing the risk of certain cancers via serum markers and risk assessment for coronary heart disease.
    Moyad MA
    Urol Oncol; 2004; 22(6):485-9. PubMed ID: 15610866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?
    Genest J
    Can J Cardiol; 2004 Aug; 20 Suppl B():89B-92B. PubMed ID: 15309211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of subclinical coronary atherosclerosis and National Cholesterol Education Panel guidelines in asymptomatic Brazilian men.
    Nasir K; Santos RD; Roguin A; Carvalho JA; Meneghello R; Blumenthal RS
    Int J Cardiol; 2006 Mar; 108(1):68-75. PubMed ID: 16516700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular risk markers in schoolchildren from five provinces of eastern Colombia].
    Villarreal E; Forero Y; Poveda E; Baracaldo C; López E
    Biomedica; 2008 Mar; 28(1):38-49. PubMed ID: 18645660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-high-density lipoprotein cholesterol in secondary prevention of coronary artery disease: a unique risk factor or redundant information?
    Holcombe SM; Brubaker PH
    J Cardiopulm Rehabil Prev; 2007; 27(6):386-9. PubMed ID: 18197073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should high sensitive C-reactive protein measurement be included in health screening packages?
    Hawkins RC; Leong L
    Singapore Med J; 2006 Oct; 47(10):837-40. PubMed ID: 16990957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.
    Reynolds TM
    J Tissue Viability; 2008 Nov; 17(4):115-20. PubMed ID: 19061825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein: a new risk assessment tool for cardiovascular disease.
    Clearfield MB
    J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention?
    Moyad MA; Carroll PR
    Urol Clin North Am; 2004 May; 31(2):301-11. PubMed ID: 15123409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk assessment in the patient with established peripheral arterial disease.
    Haugen S; Casserly IP; Regensteiner JG; Hiatt WR
    Vasc Med; 2007 Nov; 12(4):343-50. PubMed ID: 18048472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-reactive protein is an essential aspect of cardiovascular risk factor stratification.
    Yeh ET
    Can J Cardiol; 2004 Aug; 20 Suppl B():93B-96B. PubMed ID: 15309212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homocysteine increases the risk associated with hyperlipidaemia.
    Daly C; Fitzgerald AP; O'Callaghan P; Collins P; Cooney MT; Graham IM;
    Eur J Cardiovasc Prev Rehabil; 2009 Apr; 16(2):150-5. PubMed ID: 19276985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
    Anderson JL
    Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers.
    Rothenbacher D; Brenner H; März W; Koenig W
    Eur Heart J; 2005 Aug; 26(16):1640-6. PubMed ID: 15932907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a global risk educational tool on primary coronary prevention: the Atherosclerosis Assessment Via Total Risk (AVIATOR) study.
    Jacobson TA; Gutkin SW; Harper CR
    Curr Med Res Opin; 2006 Jun; 22(6):1065-73. PubMed ID: 16846539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer and coronary heart disease: correlation or coincidence?
    Moyad MA; Sonnleithner M
    Urol Clin North Am; 2004 May; 31(2):207-12. PubMed ID: 15123400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.